Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15884328 | 0.79 | NQO2 (0.34) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL23147517 | 0.79 | CRHBP (0.36) | EGFRRPS6KA5RPS6KA4NR4A2CRHBP | |
| SCHEMBL29582669 | 0.76 | EGFR (0.40) | EGFRADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL796213 | 0.76 | ACHE (0.39) | EGFRRPS6KA5RPS6KA4ADRA1ANR4A2 | |
| SCHEMBL22715644 | 0.76 | NR4A2 (0.47) | EGFRRPS6KA5RPS6KA4NR4A2 | |
| SCHEMBL24422788 | 0.76 | EGFR (0.40) | EGFRADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL15884240 | 0.76 | NQO2 (0.36) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29472071 | 0.76 | ACHE (0.39) | EGFRRPS6KA5RPS6KA4ADRA1ANR4A2 | |
| SCHEMBL14905208 | 0.74 | EGFR (0.39) | EGFR | |
| SCHEMBL14905211 | 0.72 | EGFR (0.38) | EGFRADRA2AADRA2BADRA2CNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | EGFR 592/4885RPS6KA5 125/4885RPS6KA4 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.